| 1979 |
― |
― |
ATG-Fresenius® S (now Grafalon®) is manufactured for the first time |
| 1981 |
― |
― |
First clinical use in organ transplantation |
| 1989 |
― |
― |
First clinical use of the ATG-Fresenius® S polyclonal antibody in stem cell transplantation |
| 2010 |
― |
― |
FDA grants orphan drug status and fast track designation for the development of ATG-Fresenius® S for prevention of GVHD in the United States |
| 2011 |
― |
― |
German Health Authorities (PEI) approves ATG-Fresenius® S for GVHD prophylaxis in stem cell transplantation in Germany |
| 2013 |
― |
― |
Fresenius Biotech becomes Neovii |
| 2014 |
― |
― |
Neovii global headquarters are established in Rapperswil, Switzerland |
| 2015 |
― |
― |
ATG-Fresenius® S is re-branded and launched as GRAFALON®. |
